Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination

J Immunother Cancer. 2024 Apr 24;12(4):e008151. doi: 10.1136/jitc-2023-008151.

Abstract

We describe three cases of critical acute myositis with myocarditis occurring within 22 days of each other at a single institution, all within 1 month of receiving the initial cycle of the anti-PD-1 drug pembrolizumab. Analysis of T cell receptor repertoires from peripheral blood and tissues revealed a high degree of clonal expansion and public clones between cases, with several T cell clones expanded within the skeletal muscle putatively recognizing viral epitopes. All patients had recently received a COVID-19 mRNA booster vaccine prior to treatment and were positive for SARS-CoV2 Spike antibody. In conclusion, we report a series of unusually severe myositis and myocarditis following PD-1 blockade and the COVID-19 mRNA vaccination.

Keywords: Case Reports; Immune Checkpoint Inhibitors; Melanoma; Receptors, Antigen; T-Lymphocytes.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • COVID-19 Vaccines / adverse effects
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects
  • Immune Checkpoint Inhibitors / therapeutic use
  • Male
  • Middle Aged
  • Myocarditis* / chemically induced
  • Myositis* / chemically induced
  • SARS-CoV-2* / immunology
  • Vaccination / adverse effects

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab
  • COVID-19 Vaccines
  • Immune Checkpoint Inhibitors